This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

PC30246J Submission of Missing Parts For Appln. No. 10/723,140

Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
Mail Stop: Missing Parts, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 22nd day of April 2004.

Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

JOHAN WILHELM STJERNSCHANTZ, et al.

Serial No.: 10/723,140

Confirmation No.: 9449

Filed: November 25, 2003

For: PROSTAGLANDIN DERIVATIVES FOR

THE TREATMENT OF GLAUCOMA OR

OCULAR HYPERTENSION

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Mail Stop: Missing Parts

Honorable Commissioner For Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUBMISSION OF MISSING PARTS

Sir:

In response to the Notice To File Missing Parts Of Application (Filed Under 37 CFR §1.53(b)) dated March 11, 2004, in the above-identified application, Applicant submits herewith all missing parts, namely, a signed Declaration in accordance with 37 CFR §1.63. A copy of the Notice To File Missing Parts of Nonprovisional Application is enclosed.

A signed Declaration was previously submitted with the application filed on November 25, 2003. Please carefully review the enclosed copy of the Declaration for the inventors' signatures.

Applicants do not believe the \$130.00 fee is necessary. However, to expedite the allowance of the application, please charge \$130.00, the fee set forth in 37 CFR §1.16(e), to Deposit Account No. 500329. (A duplicate of this sheet is enclosed.) If any other fees are due in connection with the filing of this response, including any fee for a required extension of time under 37 CFR 1.136(a), for which Applicant hereby petitions, please charge all necessary fees to the deposit account.

Respectfully submitted,

Date: HPCI 2

oseph F. Reidy

Attorney For Applicants/ Registration No. 39,340

Pfizer Inc.

Patent Department 10777 Science Center Drive San Diego, California 92121

Phone: (858) 622-7320 Fax: (858) 678-8233